HARMONY JPM 2026 PRESENTATION NO BUILDS for Web -FINAL.pdf

1、Copyright 2026 Harmony Biosciences.All rights reserved.44th AnnualJ.P.Morgan Healthcare ConferenceJEFFREY M.DAYNO,MDJanuary 13,2026|San FranciscoForward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

2、All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements,including statements regarding our full year 2026 net product revenue for WAKIX,expectations for the growth and value of WAKIX,plans to submit an NDA for pit

3、olisant GR;plans to conduct trials,collect or receive data,or continue investigating any of our product candidates or potential indications;our plans to extend the pitolisant franchise into the 2040s;our future results of operations and financial position,business strategy,products,prospective produ

4、cts,product approvals,the plans and objectives of management for future operations and future results of anticipated products.These statements are neither promises nor guarantees,but involve known and unknown risks,uncertainties and other important factors that may cause our actual results,performan

5、ce or achievements to be materially different from any future results,performance or achievements expressed or implied by the forward-looking statements,including,but not limited to,the following:our commercialization efforts and strategy for WAKIX and,if approved,our other product candidates;the ra

6、te and degree of market acceptance and clinical utility of pitolisant in additional indications,if approved,and any other product candidates we may develop or acquire,if approved;our research and development plans,including our efforts to explore the therapeutic potential of pitolisant in additional